Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

Jason M. Broderick @jasoncology
Published: Saturday, Jun 04, 2016

Hossein Borghaei, DO

Hossein Borghaei, DO

Two-year follow-up data showed sustained improvements in overall survival (OS) with nivolumab (Opdivo) in pretreated patients with either nonsquamous or squamous non–small cell lung cancer (NSCLC) in updated findings from the phase III CheckMate-057 and -017 trials presented at the 2016 ASCO Annual Meeting.

In the CheckMate-057 trial, the 2-year OS rate in patients with nonsquamous NSCLC was 29% with nivolumab versus 16% with docetaxel. In the CheckMate-017 study, patients with squamous NSCLC who received nivolumab had a 2-year OS rate of 23% (29/135) compared with 8% in the docetaxel group. In both trials, nivolumab continued to have a more favorable safety profile than docetaxel.

“These results give us confirmation that the drug is active and that patients do truly benefit from immunotherapy,” lead study author Hossein Borghaei, DO, chief of Thoracic Oncology at Fox Chase Cancer Center, said in an interview with OncLive. “As far as 2-year survival data goes with a single agent in the second-line setting for a very difficult patient population and disease, the data are very exciting and very much confirmatory in favor of nivolumab.”

In the 2-year follow-up, PD-L1 status was still not linked to survival in CheckMate-017; however, in CheckMate-057, stronger OS outcomes were again observed in PD-L1–positive patients, including a 57% reduction in the risk of death at 2 years for those with the highest PD-L1 levels.

Based on the initial data from the CheckMate-057 and -017 studies, nivolumab was previously approved by the FDA for use in the treatment of patients with nonsquamous or squamous NSCLC who have progressed on platinum-based chemotherapy.

CheckMate-057

The open-label CheckMate-057 trial randomized 582 patients with advanced nonsquamous NSCLC after the failure of platinum-based doublet chemotherapy to nivolumab at 3 mg/kg IV every 2 weeks (n = 292) or docetaxel at 75 mg/m2 intravenously every 3 weeks (n = 290). The treatments were administered until disease progression or unacceptable toxicity. Patients received a median of 6 and 4 doses in the nivolumab and docetaxel arms, respectively.  

Patients had an ECOG performance status of 0 or 1. The median patient age was 61 years in the nivolumab arm and 64 years in the docetaxel cohort. Prior maintenance with bevacizumab, pemetrexed, or erlotinib was allowed, as was TKI therapy for known EGFR mutations or ALK translocation. Forty-percent and 38% of patients in the nivolumab and docetaxel arms, respectively, had received prior maintenance therapy. In the nivolumab arm, 15% of patients were EGFR-positive and 4% were ALK-positive, with comparable rates of 13% and 3%, respectively, in the docetaxel group.

OS was the primary endpoint, with secondary objectives focused on progression-free survival (PFS), objective response rate (ORR) per RECIST v1.1, efficacy by PD-L1 expression, and safety.

The study was stopped early after an independent monitoring panel determined the primary endpoint of improved OS had been reached. Eligible patients were allowed to continue treatment or cross over to the nivolumab arm in an open-label extension of the study.

Six percent (n = 16) of patients in the docetaxel arm crossed over to receive nivolumab.

Fifty-five percent (25/45) of the patients initially randomized to docetaxel who were alive at 2 years received an anti­–PD-L1 or anti­–CTLA-4 agent through crossover or a subsequent line of treatment.

The previously reported 1-year OS rates were 50.5% versus 39.0%, with nivolumab versus docetaxel, respectively. The median OS at 2 years was 12.2 months (95% CI, 9.7-15.1) with nivolumab versus 9.5 months (95% CI, 8.1-10.7) with docetaxel (HR, 0.75; 95% CI, 0.63-0.91).

The 2-year PFS rate was 12% with nivolumab versus 1% with docetaxel. The median PFS was 2.3 months (95% CI; 2.2-3.4) versus 4.3 months (95% CI, 3.4-4.9), respectively (HR, 0.89; 0.75-1.07).

The CheckMate-57 researchers measured PD-L1 levels in pretreatment tumor biopsies with the Dako automated IHC assay. At the 2-year analysis, higher PD-L1 expression continued to be associated with improved survival outcomes among the 78% (n = 455) of patients for whom PD-L1 status was detectable.

Among patients with PD-L1 expression on ≥1% of tumor cells, the 2-year OS rate was 37% versus 17% with nivolumab versus docetaxel, respectively (HR, 0.62; 95% CI, 0.47-0.83). At PD-L1 levels ≥5%, the 2-year OS rates were 44% versus 14%, respectively (HR, 0.48; 95% CI, 0.34-0.68), and at PD-L1 levels ≥10%, the rates were 45% versus 13%, respectively (HR, 0.43; 95% CI, 0.30-0.62). Two-year OS rates were similar between the nivolumab and docetaxel arms among patients who did not express PD-L1: 25% versus 18% (HR, 0.91; 95% CI, 0.67-1.22).


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x